ClinicalTrials.gg
Active, not recruitingNCT06284876Updated Nov 6, 2026

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

A Phase 3 interventional study of Ilaprazole and Lansoprazole in Peptic Ulcer, sponsored by Il-Yang Pharm. Co., Ltd.. Active, not recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 3, Interventional, and Prevention

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.

Planned enrollment
5th of 16
416 · median 344
Started
2024
with 1 other
Phase 3
7 of 19
2 open now
Registered
16th of 19
by date
Lead sponsor
2 of 19
Il-Yang Pharm. Co., Ltd.

Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 16th registered.

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

Browse Peptic Ulcer studies →

Open to participants now

4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Peptic Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24

Read the detailed description

Not provided

03

Conditions studied

  • Peptic Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult males and females aged 19 years or older on the day of
  2. Subjects requiring continuous treatment or receiving treatment with NSAIDs
  3. Subjects with at least one of following peptic ulcer risk factors at the time of Screening
  4. Subjects who have provided voluntary informed consent for the study participation after the study is explained

Exclusion criteria

Exclusion Criteria:

  1. Subjects with Gastroesophageal varices, Esophageal stricture or ulcerous stenosis, Gastrointestinal bleeding or perforation, Esophageal dysplasia and else based on the screening EGD results.
  2. Subjects with inflammatory bowel diseases, pancreatitis, pyloric obstruction, and primary esophageal motility disorder
  3. Subjects with confirmed history of within 5 years prior to Screening
  4. Positive (HIV) antigen/antibody at Screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
416 participants (estimated)

Study arms

  • Experimental
    Ilaprazole 10 mg

    Take Ilaprazole 10 mg 1 tablet + Placebo of Lansoprazole 15 mg 1 capsule by mouth, with water, once daily.

    Drug: Ilaprazole · Drug: Lansoprazole Placebo

  • Active comparator
    Lansoprazole 15 mg

    Take Lansoprazole 15 mg 1 capsule + Placebo of Ilaprazole 10 mg 1 tablet by mouth, with water, once daily.

    Drug: Lansoprazole · Drug: Ilaprazole Placebo

Interventions

  • Ilaprazole 10 mg

    Also known as: Noltec(the brand name)

  • Lansoprazole 15 mg

    Also known as: Lanston(the brand name)

  • DrugIlaprazole Placebo

    Placebo of Ilaprazole 10 mg

    Also known as: Ilaprazole Placebo-matching tablet

  • DrugLansoprazole Placebo

    Placebo of Lansoprazole 15 mg

    Also known as: Lansoprazole Placebo-matching tablet

06

What researchers measure

Primary outcomes

  1. Ilaprazole, Lansoprazole peptic ulcer

    Proportion of subjects with newly developed peptic ulcer until Week 24 after the IP treatment

    Time frame: at 24 weeks

Secondary outcomes

  1. Ilaprazole, Lansoprazole peptic ulcer

    Proportion of subjects with newly developed peptic ulcer until Week 12 after the IP treatment

    Time frame: at 12 weeks

  2. Ilaprazole, Lansoprazole GI bleeding

    Proportion of subjects with upper GI bleeding by Week 12 and Week 24 after the IP treatment

    Time frame: at 12, 24 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Aug 2027, 37 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Aug 2027 and completion Feb 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 29, 2024
StartActual
Jul 23, 2024
Primary completionEst.
Aug 30, 2027was Aug 2026
CompletionEst.
Feb 28, 2028was Feb 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Primary completion
Aug 30, 2026→Aug 30, 2027
Nov 6, 2026
Study completion
Feb 28, 2027→Feb 28, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 30, 2026→Aug 30, 2027
    Study completion Feb 28, 2027→Feb 28, 2028
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06284876
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Jul 23, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

JungSoo Song, M.D.
principal investigator · Chung-Ang University Hospital Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ilaprazole

Start the discussion